474 related articles for article (PubMed ID: 29633869)
1. Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1.
McPherson TD; Sobieszczyk ME; Markowitz M
Expert Opin Investig Drugs; 2018 Apr; 27(4):413-420. PubMed ID: 29633869
[TBL] [Abstract][Full Text] [Related]
2. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.
Landovitz RJ; Donnell D; Clement ME; Hanscom B; Cottle L; Coelho L; Cabello R; Chariyalertsak S; Dunne EF; Frank I; Gallardo-Cartagena JA; Gaur AH; Gonzales P; Tran HV; Hinojosa JC; Kallas EG; Kelley CF; Losso MH; Madruga JV; Middelkoop K; Phanuphak N; Santos B; Sued O; Valencia Huamaní J; Overton ET; Swaminathan S; Del Rio C; Gulick RM; Richardson P; Sullivan P; Piwowar-Manning E; Marzinke M; Hendrix C; Li M; Wang Z; Marrazzo J; Daar E; Asmelash A; Brown TT; Anderson P; Eshleman SH; Bryan M; Blanchette C; Lucas J; Psaros C; Safren S; Sugarman J; Scott H; Eron JJ; Fields SD; Sista ND; Gomez-Feliciano K; Jennings A; Kofron RM; Holtz TH; Shin K; Rooney JF; Smith KY; Spreen W; Margolis D; Rinehart A; Adeyeye A; Cohen MS; McCauley M; Grinsztejn B;
N Engl J Med; 2021 Aug; 385(7):595-608. PubMed ID: 34379922
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
Marzinke MA; Grinsztejn B; Fogel JM; Piwowar-Manning E; Li M; Weng L; McCauley M; Cummings V; Ahmed S; Haines CD; Bushman LR; Petropoulos C; Persaud D; Adeyeye A; Kofron R; Rinehart A; St Clair M; Rooney JF; Pryluka D; Coelho L; Gaur A; Middelkoop K; Phanuphak N; Cohen MS; Hendrix CW; Anderson P; Hanscom B; Donnell D; Landovitz RJ; Eshleman SH
J Infect Dis; 2021 Nov; 224(9):1581-1592. PubMed ID: 33740057
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of cabotegravir for HIV treatment and prevention.
Canetti D; Spagnuolo V
Expert Opin Pharmacother; 2021 Mar; 22(4):403-414. PubMed ID: 33112699
[No Abstract] [Full Text] [Related]
5. Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis.
Wang W; Zhao S; Wu Y; Duan W; Li S; Li Z; Guo C; Wang W; Zhang T; Wu H; Huang X
JMIR Public Health Surveill; 2023 Jul; 9():e46767. PubMed ID: 37498645
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
Landovitz RJ; Li S; Grinsztejn B; Dawood H; Liu AY; Magnus M; Hosseinipour MC; Panchia R; Cottle L; Chau G; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; Zhang Y; Tolley E; Sugarman J; Kofron R; Adeyeye A; Burns D; Rinehart AR; Margolis D; Spreen WR; Cohen MS; McCauley M; Eron JJ
PLoS Med; 2018 Nov; 15(11):e1002690. PubMed ID: 30408115
[TBL] [Abstract][Full Text] [Related]
7. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
[TBL] [Abstract][Full Text] [Related]
8. Global HIV Incidence Analysis and Implications for Affordability Using Long-Acting Cabotegravir Versus Continuous and Event-Driven Oral Preexposure Prophylaxis.
Sharma I; Hill A
Clin Infect Dis; 2024 Feb; 78(2):386-394. PubMed ID: 37665213
[TBL] [Abstract][Full Text] [Related]
9. A literature review of the patent application publications on cabotegravir - an HIV integrase strand transfer inhibitor.
Kovač L; Časar Z
Expert Opin Ther Pat; 2020 Mar; 30(3):195-208. PubMed ID: 31944142
[No Abstract] [Full Text] [Related]
10. Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
Eshleman SH; Fogel JM; Piwowar-Manning E; Chau G; Cummings V; Agyei Y; Richardson P; Sullivan P; Haines CD; Bushman LR; Petropoulos C; Persaud D; Kofron R; Hendrix CW; Anderson PL; Farrior J; Mellors J; Adeyeye A; Rinehart A; St Clair M; Ford S; Rooney JF; Mathew CA; Hunidzarira P; Spooner E; Mpendo J; Nair G; Cohen MS; Hughes JP; Hosseinipour M; Hanscom B; Delany-Moretlwe S; Marzinke MA
J Infect Dis; 2022 May; 225(10):1741-1749. PubMed ID: 35301540
[TBL] [Abstract][Full Text] [Related]
11. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Orkin C; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Overton ET; Girard PM; Oka S; Walmsley S; Bettacchi C; Brinson C; Philibert P; Lombaard J; St Clair M; Crauwels H; Ford SL; Patel P; Chounta V; D'Amico R; Vanveggel S; Dorey D; Cutrell A; Griffith S; Margolis DA; Williams PE; Parys W; Smith KY; Spreen WR
N Engl J Med; 2020 Mar; 382(12):1124-1135. PubMed ID: 32130806
[TBL] [Abstract][Full Text] [Related]
12. Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis.
Durham SH; Milam A; Waer D; Chahine EB
Ann Pharmacother; 2023 Mar; 57(3):306-316. PubMed ID: 35778802
[TBL] [Abstract][Full Text] [Related]
13. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
Swindells S; Andrade-Villanueva JF; Richmond GJ; Rizzardini G; Baumgarten A; Masiá M; Latiff G; Pokrovsky V; Bredeek F; Smith G; Cahn P; Kim YS; Ford SL; Talarico CL; Patel P; Chounta V; Crauwels H; Parys W; Vanveggel S; Mrus J; Huang J; Harrington CM; Hudson KJ; Margolis DA; Smith KY; Williams PE; Spreen WR
N Engl J Med; 2020 Mar; 382(12):1112-1123. PubMed ID: 32130809
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection.
Radzio-Basu J; Council O; Cong ME; Ruone S; Newton A; Wei X; Mitchell J; Ellis S; Petropoulos CJ; Huang W; Spreen W; Heneine W; García-Lerma JG
Nat Commun; 2019 May; 10(1):2005. PubMed ID: 31043606
[TBL] [Abstract][Full Text] [Related]
15. A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV.
Bares SH; Scarsi KK
Curr Opin HIV AIDS; 2022 Jan; 17(1):22-31. PubMed ID: 34871188
[TBL] [Abstract][Full Text] [Related]
16. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
Murray MI; Markowitz M; Frank I; Grant RM; Mayer KH; Hudson KJ; Stancil BS; Ford SL; Patel P; Rinehart AR; Spreen WR; Margolis DA
HIV Clin Trials; 2018 Aug; 19(4):129-138. PubMed ID: 30445896
[TBL] [Abstract][Full Text] [Related]
17. Long-acting injectable cabotegravir for the prevention of HIV infection.
Clement ME; Kofron R; Landovitz RJ
Curr Opin HIV AIDS; 2020 Jan; 15(1):19-26. PubMed ID: 31644481
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States.
Brogan AJ; Davis AE; Mellott CE; Fraysse J; Metzner AA; Oglesby AK
Pharmacoeconomics; 2024 Apr; 42(4):447-461. PubMed ID: 38267806
[TBL] [Abstract][Full Text] [Related]
19. Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.
Blair HA
Drugs; 2022 Sep; 82(14):1489-1498. PubMed ID: 36255686
[TBL] [Abstract][Full Text] [Related]
20. Cabotegravir long-acting for HIV-1 prevention.
Andrews CD; Heneine W
Curr Opin HIV AIDS; 2015 Jul; 10(4):258-63. PubMed ID: 26049951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
